Results showed that some genomic variants, such as TP53 56 and KMT2D 57, associated with worse clinical outcomes and tumor invasion were enriched in CTNND1-high group, while CTNND1-low groups had higher mutant frequency of some gene associated with immune infiltration and favorable outcomes, such as CACNA1C 58 and LMO7 59 (Supplementary Figure 8). This evidence concerns the gene CTNND1 and neoplasm.